New Clinical Results from APOLLO OLE Study at 2018 AANEM Annual Meeting

New Clinical Results from APOLLO OLE Study at 2018 AANEM Annual Meeting

We presented new 12-month efficacy and safety data with patisiran from the APOLLO Global Open Label Extension (OLE) Study at the 2018 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting, held October 10-13, 2018 in Washington, DC.

Gonzalez-Duarte et al. – “Long-Term Use of Patisiran, an Investigational RNAi Therpaeutic, in Patients with Hereditary Transthyretin-Mediated Amyloidosis: 12 Month Efficacy and Safety Data from Global Open Label Extension (OLE) Study”



SIGN UP FOR EMAIL UPDATES

Receive news and updates on the work at Alnylam that affects you most.